SequelSEC

bioAffinity Technologies, Inc. BIAF

Services-Commercial Physical & Biological Research · CIK 0001712762 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.51M
Fiscal year ended 2026-06-30
Operating income
-$3.33M
Fiscal year ended 2026-06-30
Free cash flow
-$3.29M
Fiscal year ended 2026-06-30

bioAffinity Technologies, Inc. (BIAF) reported revenue of $1.51M and net income of -$3.37M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from bioAffinity Technologies, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

bioAffinity Technologies, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.51M$1.35M$1.59M$1.45M$1.27M$1.85M$2.21M$2.35M$2.40M$2.41M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.33M-$3.62M-$3.14M-$2.29M-$2.52M-$2.63M-$2.95M-$1.97M-$2.09M-$1.95M
Net income-$3.37M-$3.63M-$3.14M-$5.05M-$4.06M-$2.66M-$2.97M-$2.00M-$2.11M-$1.96M
Research & development$361.58K$349.71K$374.01K$330.59K$311.37K$367.39K$390.66K$274.50K$402.43K$393.64K
Weighted-average diluted sharesshares 5.23Mshares 4.49MUnavailableshares 1.07MUnavailableUnavailableUnavailableUnavailableshares 11.39Mshares 9.92M
Pretax income-$3.37M-$3.63M-$3.13M-$5.05M-$4.03M-$2.65M-$2.97M-$2.00M-$2.10M-$1.96M
Income tax expenseUnavailableUnavailable$3.18K$3.18K$28.98K$8.70K$0$2.56K$5.42K$3.67K
Diluted EPS$-0.64$-0.81Unavailable$-4.74$-5.07$-4.80Unavailable$-4.84$-0.19$-0.20
Selling, general & administrative$2.86M$3.24M$3.04M$2.21M$2.21M$2.45M$2.92M$2.36M$2.47M$2.19M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

bioAffinity Technologies, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$2.43M$3.10M$6.45M$7.67M$802.84K$444.71K$1.11M$756.58K$801.31K$2.45M
Total assets$7.62M$7.95M$10.96M$11.55M$4.75M$5.55M$6.51M$6.55M$6.66M$8.05M
Current assets$3.87M$4.34M$7.57M$8.61M$1.67M$1.86M$2.70M$2.55M$2.68M$3.93M
Total liabilities$3.85M$4.28M$3.68M$2.64M$6.89M$4.11M$3.91M$3.43M$3.22M$2.79M
Current liabilities$2.68M$3.18M$2.91M$2.36M$2.59M$3.42M$3.10M$2.49M$2.33M$1.77M
Total equity incl. NCI$3.77M$3.65M$7.28M$8.90M-$2.14M$1.44M$2.60M$3.12M$3.43M$5.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$82.38K$77.89K$53.55K$35.23K$43.97K$38.78K$27.61K$25.36K$29.77K$9.49K
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$969.84K$836.21K$761.90K$940.76K$1.17M$1.38M$987.31K$782.94K$848.10K$383.99K

Cash flow

bioAffinity Technologies, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.20M-$3.23M-$2.56M-$2.48M-$2.65M-$1.64M-$1.68M-$1.71M-$1.53M-$2.35M
Capital expenditures$89.97K$5.66K$1-$3.65K$13.43K$50.79K$1$9.41K$28.28K$41.39K
Investing cash flow-$89.97K-$5.66K-$1$3.65K-$13.43K-$50.79K-$1-$9.41K-$28.28K-$41.39K
Financing cash flow$2.62M-$118.51K$1.34M$9.34M$3.02M$1.03M$2.03M$1.67M-$91.14K$2.02M
Net change in cash-$668.65K-$3.35M-$1.22M$6.87M$358.13K-$660.58K$348.71K-$44.73K-$1.65M-$368.40K
Stock-based compensation$784.94K$14.34K$66.12K$67.13K$211.61K$326.62K$234.09K$185.69K$286.20K$283.71K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$61.56K$114.52K$123.66K$113.36K$113.23K$154.59K$153.63K$151.30K$151.07K$149.64K

Derived

bioAffinity Technologies, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$3.29M-$3.23M-$2.56MUnavailable-$2.66M-$1.69M-$1.68M-$1.72M-$1.56M-$2.39M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-220.8%-267.6%-196.9%-158.6%-198.2%-141.7%-133.5%-84.0%-87.1%-80.8%
FCF margin-217.9%-239.2%-160.7%Unavailable-209.6%-91.3%-76.0%-73.1%-65.1%-99.2%
SBC / revenue52.0%1.1%4.2%4.6%16.7%17.6%10.6%7.9%11.9%11.8%
Current ratio1.44x1.36x2.60x3.65x0.64x0.55x0.87x1.02x1.15x2.22x
Revenue YoY growth19.0%-27.1%-27.8%-38.5%-47.1%-23.0%-0.3%687.4%12047.4%33.2%
Net margin-222.8%-268.6%-197.0%-349.3%-319.9%-143.5%-134.4%-85.1%-88.0%-81.5%
R&D / revenue23.9%25.9%23.5%22.9%24.5%19.8%17.7%11.7%16.8%16.4%
CapEx / revenue6.0%0.4%0.0%-0.3%1.1%2.7%0.0%0.4%1.2%1.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIAF in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-03-31

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.